Enhanced stem cell compositions

Enhanced stem cell compositions

  • CN 104,066,837 B
  • Filed: 11/29/2012
  • Issued: 12/08/2020
  • Est. Priority Date: 12/02/2011
  • Status: Active Grant
First Claim
Patent Images

1. Human hematopoietic stem or progenitor cells, wherein said cells have been contacted ex vivo with one or more prostaglandin pathway agonists and one or more glucocorticoids to increase CXCR4 gene expression in said cells by at least 29.4-fold as compared to an uncontacted hematopoietic stem or progenitor cell, wherein said one or more prostaglandin pathway agonists are selected from PGE215(S) -15-methyl PGE220-Ethyl PGE2And dmPGE2And the one or more glucocorticoids are selected from the group consisting of hydrocortisone, dexamethasone, medrysone, alclomethasone and triamcinolone.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×